Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AORT Stock Forecast 2026-2027
$24.03
Current Price
$1.17B
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AORT Price Targets
+99.8%
To High Target of $48.00
+78.9%
To Median Target of $43.00
+49.8%
To Low Target of $36.00
AORT Price Momentum
+1.9%
1 Week Change
+14.0%
1 Month Change
-23.0%
1 Year Change
-47.3%
Year-to-Date Change
-50.2%
From 52W High of $48.25
+25.4%
From 52W Low of $19.16
📊 TOP ANALYST CALLS
Did AORT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Artivion is one of their latest high-conviction picks.
Latest AORT Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, AORT has a bullish consensus with a median price target of $43.00 (ranging from $36.00 to $48.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $24.03, the median forecast implies a 78.9% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by William Plovanic at Canaccord Genuity, suggesting a 49.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AORT Analyst Ratings
8
Buy
0
Hold
0
Sell
AORT Price Target Range
Low
$36.00
Average
$43.00
High
$48.00
Current: $24.03
Latest AORT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AORT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 16, 2026 | Canaccord Genuity | William Plovanic | Buy | Maintains | $36.00 |
| May 8, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| May 8, 2026 | Needham | Buy | Maintains | $N/A | |
| Apr 10, 2026 | Ladenburg Thalmann | Buy | Upgrade | $N/A | |
| Apr 7, 2026 | Needham | Buy | Reiterates | $N/A | |
| Feb 13, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 2, 2026 | Needham | Buy | Reiterates | $N/A | |
| Nov 7, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 7, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Nov 7, 2025 | Needham | Buy | Maintains | $N/A | |
| Oct 10, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Sep 29, 2025 | Stifel | Buy | Maintains | $N/A | |
| Sep 29, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 22, 2025 | Needham | Buy | Maintains | $N/A | |
| Aug 13, 2025 | Ladenburg Thalmann | Neutral | Downgrade | $N/A | |
| Aug 8, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 8, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Aug 8, 2025 | Stifel | Buy | Maintains | $N/A | |
| Aug 8, 2025 | Needham | Buy | Maintains | $N/A | |
| Jun 17, 2025 | Canaccord Genuity | Buy | Initiates | $N/A |
Artivion Inc. (AORT) Competitors
The following stocks are similar to Artivion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Artivion Inc. (AORT) Financial Data
Artivion Inc. has a market capitalization of $1.17B with a P/E ratio of 96.4x. The company generates $458.69M in trailing twelve-month revenue with a 2.5% profit margin.
Revenue growth is +17.5% quarter-over-quarter, while maintaining an operating margin of +5.2% and return on equity of +3.1%.
Valuation Metrics
Market Cap
$1.17B
Enterprise Value
$1.37B
P/E Ratio
96.4x
PEG Ratio
-0.2x
Price/Sales
2.5x
Growth & Margins
Revenue Growth (YoY)
+17.5%
Gross Margin
+64.9%
Operating Margin
+5.2%
Net Margin
+2.5%
EPS Growth
+17.5%
Financial Health
Cash/Price Ratio
+4.8%
Current Ratio
3.9x
Debt/Equity
57.3x
ROE
+3.1%
ROA
+2.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Artivion Inc. (AORT) Business Model
About Artivion Inc.
What They Do
Develops innovative medical devices for cardiac surgery.
Business Model
The company generates revenue by developing, manufacturing, and selling advanced medical devices that focus on cardiac and vascular surgery. Its product offerings include life-saving technologies related to cryopreservation and heart valve therapies, which are essential for healthcare professionals and surgeons in treating complex heart conditions.
Additional Information
Artivion Inc. operates on a global scale and is headquartered in the United States, emphasizing innovation and quality in its product development. The company plays a vital role in enhancing surgical efficiency and improving patient outcomes in cardiovascular treatment and transplant medicine.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,600
CEO
Mr. James Patrick Mackin
Country
United States
IPO Year
1993
Website
artivion.comArtivion Inc. (AORT) Latest News & Analysis
Latest News
Quick Summary
AORT received FDA approval for AMDS, facilitating hospital adoption and potentially accessing a $150 million annual U.S. market.
Why It Matters
AORT's FDA approval enhances market access, potentially increasing revenue by $150 million annually, signaling growth potential and boosting investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Artivion, Inc. (NYSE: AORT) received FDA approval for the AMDS Hybrid Prosthesis, targeting acute Debakey Type I aortic dissections, potentially impacting 60% of cases.
Why It Matters
FDA approval of the AMDS Hybrid Prosthesis enhances Artivion's product portfolio, potentially increasing market share and revenue by addressing a significant portion of aortic dissection cases.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Artivion received FDA approval for AMDS, enhancing market access in a $150M U.S. market. AORT reports double-digit revenue growth, 26% EBITDA increase, and nearing 65% gross margins.
Why It Matters
Artivion's FDA approval of AMDS opens a $150M market and signals strong clinical benefits, likely driving revenue growth and profitability, which can enhance investor confidence and stock performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Artivion, Inc. (NYSE: AORT) will present at the 2026 Truist Securities MedTech Conference on June 16, 2026, at 1:00 p.m. at the Boston Harbor Hotel.
Why It Matters
Artivion's participation in a major MedTech conference highlights its market visibility and potential growth, which may influence investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Artivion Completes Acquisition of Endospan Ltd.
1 month ago
Quick Summary
Artivion, Inc. (NYSE: AORT) has acquired Endospan Ltd., enhancing its capabilities in aortic disease treatment and expanding its product offerings with the NEXUS® Aortic Arch System.
Why It Matters
Artivion's acquisition of Endospan enhances its product portfolio and market position in aortic disease treatment, potentially driving growth and increasing shareholder value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Endospan has been acquired by Artivion, Inc. (NYSE: AORT) following FDA approval of the NEXUS® Aortic Arch System, aimed at treating aortic arch disease in high-risk patients.
Why It Matters
The acquisition of Endospan by Artivion enhances its product portfolio, potentially increasing market share and revenue, especially with FDA approval of the innovative NEXUS® system.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About AORT Stock
What is Artivion Inc.'s (AORT) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Artivion Inc. (AORT) has a median price target of $43.00. The highest price target is $48.00 and the lowest is $36.00.
Is AORT stock a good investment in 2027?
According to current analyst ratings, AORT has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AORT stock?
Wall Street analysts predict AORT stock could reach $43.00 in the next 12 months. This represents a 78.9% increase from the current price of $24.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Artivion Inc.'s business model?
The company generates revenue by developing, manufacturing, and selling advanced medical devices that focus on cardiac and vascular surgery. Its product offerings include life-saving technologies related to cryopreservation and heart valve therapies, which are essential for healthcare professionals and surgeons in treating complex heart conditions.
What is the highest forecasted price for AORT Artivion Inc.?
The highest price target for AORT is $48.00 from at , which represents a 99.8% increase from the current price of $24.03.
What is the lowest forecasted price for AORT Artivion Inc.?
The lowest price target for AORT is $36.00 from William Plovanic at Canaccord Genuity, which represents a 49.8% increase from the current price of $24.03.
What is the overall AORT consensus from analysts for Artivion Inc.?
The overall analyst consensus for AORT is bullish. Out of 2 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $43.00.
How accurate are AORT stock price projections?
Stock price projections, including those for Artivion Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 7:12 PM UTC